In the last decade, several neoadjuvant trials for NSCLC. patients with mediastinal lymph node involvement (N2) have been scheduled. The uniform plan is based on clinical staging, therapy clinical re-staging, surgery (when is possible) and, finally, pathological staging The precise classification of tumor during the' three different staging procedures is mandatory. Considering clinical re-staging and pathological staqinq, nowadays surgery could be considered correct for most of the patients enrolled in the neoadjuvant protocols including cases where a major clinical response has not been achieved. Several experiences demonstrated how often the clinical re-staging overesteems neoplastic tissue by fibrosis and scar and could judge as unserectablc patients with a minimal residual disease.
|Number of pages||5|
|Journal||Annali Italiani di Chirurgia|
|Publication status||Published - Nov 1999|
- Lung cancer
- N2 patients
- Neoadjuvant therapy
ASJC Scopus subject areas